← Leaderboards
Kathleen Elizabeth Corey
Massachusetts General Hospital
$4,109,943
Attributed
$8,854,861
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,854,861 · 5
By mechanism
R01$7,670,339 · 2
K23$938,143 · 1
R03$171,000 · 1
F32$75,379 · 1
Top collaborators
- Miriam Antoinette Bredella5 shared
- Georg Michael Lauer5 shared
- Karen K Miller5 shared
- Takara Leah Stanley5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Madhusmita Misra$12,646,884
- Georg Michael Lauer$24,583,765
- Stephanie Jost$7,411,250
- Raymond T Chung$38,306,004
- Marcus Altfeld$19,256,149
Others in their field
Top investigators on “Lipids”
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Alan M Fogelman · University Of California Los Angeles$57,458,120
- Paul M. Ridker · Brigham And Women'S Hospital$56,179,451
- Adrian Hernandez · Duke University$50,769,596
- Garret A Fitzgerald · University Of Pennsylvania$50,340,498
- Richard A Gibbs · Baylor College Of Medicine$49,140,324
Research focus
LipidsLiver TransplantationObesityHepaticLiverNonalcoholic SteatohepatitisCirrhosisLiver DiseasesTherapy DevelopmentAmericanAffectMassachusettsPlayGeneral HospitalsLipid MetabolismHigh PrevalenceMetabolic DiseasesInflammationLeadHistologicFibrosisLipid BiosynthesisEffective TherapyAnimals
Grant awards (19)
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2025 · DK
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$704,322
R01 · FY2024 · DK
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2023 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk$807,629
R01 · FY2022 · DK
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2022 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk$807,629
R01 · FY2021 · DK
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2021 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk$807,629
R01 · FY2020 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk$808,114
R01 · FY2019 · DK
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk$800,344
R01 · FY2018 · DK
Metabolite profiling for Coronary Artery Disease in Nonalcoholic Fatty Liver Disease$85,500
R03 · FY2018 · DK · contact PI
The Impact of Obstructive Sleep Apnea on Non-Alcoholic Fatty Liver Disease$199,379
K23 · FY2017 · DK · contact PI
Metabolite profiling for Coronary Artery Disease in Nonalcoholic Fatty Liver Disease$85,500
R03 · FY2017 · DK · contact PI
The Impact of Obstructive Sleep Apnea on Non-Alcoholic Fatty Liver Disease$184,691
K23 · FY2016 · DK · contact PI
The Impact of Obstructive Sleep Apnea on Non-Alcoholic Fatty Liver Disease$184,691
K23 · FY2015 · DK · contact PI
The Impact of Obstructive Sleep Apnea on Non-Alcoholic Fatty Liver Disease$184,691
K23 · FY2014 · DK · contact PI
The Impact of Obstructive Sleep Apnea on Non-Alcoholic Fatty Liver Disease$184,691
K23 · FY2013 · DK · contact PI
Interactions Between Hepatitis C and Serum Lipid Homeostasis$20,537
F32 · FY2010 · DK · contact PI
Interactions Between Hepatitis C and Serum Lipid Homeostasis$54,842
F32 · FY2008 · DK · contact PI